Welcome to our dedicated page for Atai Beckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtaiBeckley Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common shares and psychiatry-focused investigational drug programs. The company’s regulatory record includes proxy and governance disclosures, shareholder voting matters, operating and financial results, clinical and regulatory updates, and risk-related information tied to development programs such as BPL-003, VLS-01, and EMP-01.
Material-event filings and registration-related documents also cover capital-structure activity, public offering agreements, resale registration matters, and acquisition-related share registration connected with Beckley Psytech. Historical filings under ATAI Life Sciences N.V. and Atai Beckley N.V. provide reference for the company’s corporate transition, financing activity, governance framework, and formal disclosure of business updates.
Form 4 filing overview: ATAI Life Sciences N.V. reported that director Laurent Fischer was granted a new option award on 26 June 2025.
Key details:
- Derivative security: Stock option on ATAI common shares
- Quantity granted: 103,000 options
- Exercise price: $2.25 per share
- Expiration: 26 June 2035
- Vesting: Options vest on the earlier of (i) the day before the company’s next annual meeting or (ii) 26 June 2026.
- Ownership status: Following this transaction, the reporting person beneficially owns 103,000 derivative securities, held directly.
The filing represents a routine equity compensation grant to a non-executive director and does not disclose any purchase or sale of ATAI common shares. No cash consideration was exchanged at grant (price of derivative security recorded as $0), indicating a standard incentive award. The disclosure offers no new information on company operations, earnings, or strategic developments.
Form 4 snapshot – ATAI Life Sciences N.V. (NASDAQ: ATAI)
Director Dr. Scott Braunstein reported the grant of 103,000 non-qualified stock options on 26 Jun 2025 at an exercise price of $2.25 per common share. The options expire on 26 Jun 2035 and will vest in full on the earlier of (i) the day prior to the company’s next annual general meeting or (ii) 26 Jun 2026, providing a 12-month maximum vesting horizon. Following the award, Dr. Braunstein now beneficially owns 103,000 derivative securities; no common shares were bought or sold, and no other transactions were reported.
The filing represents routine director compensation under the company’s equity incentive plan. As the grant is at-the-money (current market price ≈ exercise price) and totals roughly <0.1% of shares outstanding, it has minimal dilution impact. Nonetheless, the award aligns the director’s incentives with long-term shareholder value, signalling continued board engagement.
Form 4 filing overview: On 06/27/2025 ATAI Life Sciences N.V. (symbol: ATAI) reported a change in beneficial ownership by Christian Angermayer, who is both a Director and 10% owner.
Key transaction: On 06/26/2025 the insider received a stock option covering 103,000 common shares at an exercise price of $2.25 per share. The award was coded "A" (grant or award) and is held directly by the reporting person.
Vesting & expiration: The option vests on the earlier of (i) the day before ATAIs next annual shareholder meeting or (ii) 06/26/2026, and it expires on 06/26/2035. No deemed execution date or other conditions were noted.
Post-transaction holdings: Following the grant, Mr. Angermayer beneficially owns 103,000 derivative securities (stock options). Table I shows no non-derivative share acquisitions or dispositions.
Investor take-away: The filing reflects a routine equity incentive grant rather than an open-market purchase or sale, so it carries limited immediate signalling value. The award incrementally increases potential dilution but has no direct impact on ATAIs cash position or current share count.